CollPlant Biotechnologies (CLGN) Equity Average (2020 - 2026)

CollPlant Biotechnologies has reported Equity Average for 7 years, with the latest figure at $5.5 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 57.59% year-over-year to $5.5 million; the trailing twelve-month figure through Mar 2026 stood at $5.5 million (down 57.59% YoY), and the FY2025 full-year result was $9.8 million, down 53.24% from the prior year.
• Equity Average for Q1 2026 stood at $5.5 million, down from $7.7 million in the prior quarter.
• The five-year high for Equity Average was $44.2 million in Q1 2022, with the low at $5.5 million in Q1 2026.
• Historically, Equity Average has averaged $24.6 million across 5 years, with a median of $26.4 million in 2024.
• Annual changes were most pronounced in 2022 — Equity Average jumped 60.21% — and 2026, when it plunged 57.59%.
• CollPlant Biotechnologies' Equity Average stood at $34.0 million in 2022, then decreased by 10.79% to $30.4 million in 2023, then sank by 49.98% to $15.2 million in 2024, then slumped by 49.36% to $7.7 million in 2025, then dropped by 28.72% to $5.5 million in 2026.
• The last three Equity Average figures came in at $5.5 million (Q1 2026), $7.7 million (Q4 2025), and $10.9 million (Q3 2025), per Business Quant data.